Selected research
Industry Growth & Trends
Global RNAi Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global RNAi Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the RNAi Therapeutics market include Novartis and Alnylam Pharmaceuticals among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global RNAi Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The RNAi Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global RNAi Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to RNAi Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global RNAi Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
RNAi Therapeutics Market by Company
Novartis
Alnylam Pharmaceuticals
RNAi Therapeutics Segment by Type
Subcutaneous Injection
Intravenous Infusion
RNAi Therapeutics Segment by Application
Cancer
Cardiovascular Disease
Genetic Disorder
Other
RNAi Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of RNAi Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Subcutaneous Injection
- Intravenous Infusion
Applications
- Cancer
- Cardiovascular Disease
- Genetic Disorder
- Other
Companies covered
- Novartis
- Alnylam Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global RNAi Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global RNAi Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global RNAi Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global RNAi Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions RNAi Therapeutics Market Size (2021-2032)
- 1.5.1 North America RNAi Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe RNAi Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific RNAi Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America RNAi Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa RNAi Therapeutics Market Size Growth Rate (2021-2032)
2 RNAi Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Subcutaneous Injection
- 2.1.2 Intravenous Infusion
- 2.2 Global RNAi Therapeutics Market Size by Type
- 2.2.1 Global RNAi Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global RNAi Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global RNAi Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global RNAi Therapeutics Market Size by Regions
- 2.3.1 North America RNAi Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe RNAi Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific RNAi Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America RNAi Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa RNAi Therapeutics Market Size Breakdown by Type (2021-2026)
3 RNAi Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer
- 3.1.2 Cardiovascular Disease
- 3.1.3 Genetic Disorder
- 3.1.4 Other
- 3.2 Global RNAi Therapeutics Market Size by Application
- 3.2.1 Global RNAi Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global RNAi Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global RNAi Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global RNAi Therapeutics Market Size by Regions
- 3.3.1 North America RNAi Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe RNAi Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific RNAi Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America RNAi Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa RNAi Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 RNAi Therapeutics Industry Trends
- 4.2 RNAi Therapeutics Industry Drivers
- 4.3 RNAi Therapeutics Industry Opportunities and Challenges
- 4.4 RNAi Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by RNAi Therapeutics Revenue (2021-2026)
- 5.2 Global RNAi Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global RNAi Therapeutics Key Company Headquarters & Area Served
- 5.4 Global RNAi Therapeutics Company, Product Type & Application
- 5.5 Global RNAi Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global RNAi Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 RNAi Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 RNAi Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novartis
- 6.1.1 Novartis Company Information
- 6.1.2 Novartis Business Overview
- 6.1.3 Novartis RNAi Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novartis RNAi Therapeutics Product Portfolio
- 6.1.5 Novartis Recent Developments
- 6.2 Alnylam Pharmaceuticals
- 6.2.1 Alnylam Pharmaceuticals Company Information
- 6.2.2 Alnylam Pharmaceuticals Business Overview
- 6.2.3 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Alnylam Pharmaceuticals RNAi Therapeutics Product Portfolio
- 6.2.5 Alnylam Pharmaceuticals Recent Developments
7 North America
- 7.1 North America RNAi Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America RNAi Therapeutics Market Size by Country (2021-2026)
- 7.3 North America RNAi Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe RNAi Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe RNAi Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe RNAi Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific RNAi Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific RNAi Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific RNAi Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America RNAi Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America RNAi Therapeutics Market Size by Country (2021-2026)
- 10.3 South America RNAi Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa RNAi Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa RNAi Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa RNAi Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst